PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) ..... see more
Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional ..... see more
Source : https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1873320?journalCode=ilal20
Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe ..... see more
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance ..... see more
S. Shahzad Mustafa There are many causes for secondary immunodeficiency (SID), which commonly presents with increased risk of infections. B-cell malignancies (multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma) and chemotherapeutics ..... see more
Source : https://link.springer.com/chapter/10.1007/978-3-030-57157-3_21
Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional ..... see more
Background Multiple myeloma is a hematologic disorder of abnormal plasma cell proliferation. Although there are some agents with different mechanisms in the clinic, the treatment of multiple myeloma is still ..... see more
Source : https://www.researchsquare.com/article/rs-153300/v1
Multiple myeloma (MM) is the second most common hematologic malignancy, and is characterized by the clonal expansion of malignant plasma cells. Despite the recent improvement in patient outcome due to ..... see more
Source : https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-021-00302-x
Request PDF | A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma | B cell maturation antigen- (BCMA) specific chimeric antigen ..... see more
Osteolytic lesions (OL) characterize symptomatic multiple myeloma. The mechanisms of how malignant plasma cells (PC) cause OL in one region while others show no signs of bone destruction despite subtotal ..... see more
Source : https://www.researchsquare.com/article/rs-146899/v1